Analysts expect that Cambrex Co. (NYSE:CBM) will report earnings of $0.31 per share for the current quarter, according to Zacks Investment Research. Two analysts have made estimates for Cambrex’s earnings, with the lowest EPS estimate coming in at $0.08 and the highest estimate coming in at $0.53. Cambrex reported earnings per share of $0.68 in the same quarter last year, which indicates a negative year over year growth rate of 54.4%. The company is expected to announce its next earnings report on Thursday, May 3rd.
According to Zacks, analysts expect that Cambrex will report full-year earnings of $2.92 per share for the current year, with EPS estimates ranging from $2.90 to $2.94. For the next fiscal year, analysts forecast that the firm will report earnings of $3.14 per share, with EPS estimates ranging from $3.01 to $3.30. Zacks’ EPS calculations are a mean average based on a survey of research analysts that that provide coverage for Cambrex.
Cambrex (NYSE:CBM) last announced its earnings results on Thursday, February 8th. The biotechnology company reported $1.27 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.10 by $0.17. The company had revenue of $182.28 million during the quarter, compared to the consensus estimate of $181.39 million. Cambrex had a net margin of 19.17% and a return on equity of 22.42%. The firm’s revenue for the quarter was up 2.5% on a year-over-year basis. During the same quarter in the prior year, the company posted $1.23 earnings per share.
Several brokerages have recently commented on CBM. Zacks Investment Research downgraded shares of Cambrex from a “hold” rating to a “sell” rating in a report on Tuesday. Longbow Research downgraded shares of Cambrex from a “buy” rating to a “neutral” rating in a report on Wednesday, February 14th. Finally, William Blair began coverage on shares of Cambrex in a research report on Tuesday, January 16th. They set an “outperform” rating for the company. Two research analysts have rated the stock with a sell rating, two have given a hold rating and two have given a buy rating to the company’s stock. The company presently has an average rating of “Hold” and an average target price of $60.00.
Shares of Cambrex stock traded down $0.35 during mid-day trading on Tuesday, hitting $54.15. 194,824 shares of the stock traded hands, compared to its average volume of 345,641. The stock has a market capitalization of $1,837.78, a P/E ratio of 17.64, a P/E/G ratio of 1.33 and a beta of 2.38. Cambrex has a 52 week low of $42.55 and a 52 week high of $62.95.
Institutional investors and hedge funds have recently bought and sold shares of the stock. Financial Gravity Companies Inc. bought a new position in Cambrex during the fourth quarter valued at about $166,000. Visionary Asset Management Inc. bought a new position in Cambrex during the third quarter valued at about $201,000. Trexquant Investment LP bought a new position in Cambrex during the third quarter valued at about $209,000. Advisor Group Inc. grew its position in Cambrex by 52.9% during the third quarter. Advisor Group Inc. now owns 4,100 shares of the biotechnology company’s stock valued at $226,000 after buying an additional 1,419 shares during the period. Finally, Sei Investments Co. grew its position in Cambrex by 3,120.9% during the third quarter. Sei Investments Co. now owns 4,155 shares of the biotechnology company’s stock valued at $228,000 after buying an additional 4,026 shares during the period.
COPYRIGHT VIOLATION WARNING: “Brokerages Expect Cambrex Co. (CBM) to Post $0.31 EPS” was first published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this report on another domain, it was copied illegally and reposted in violation of US and international copyright laws. The correct version of this report can be accessed at https://www.dispatchtribunal.com/2018/03/20/brokerages-expect-cambrex-co-cbm-to-post-0-31-eps.html.
Cambrex Company Profile
Cambrex Corporation (Cambrex) is a life sciences company. It provides products and services for the development and commercialization of generic therapeutics. It operates through four segments, which are manufacturing facilities that have been aggregated as a single segment. Its manufacturing facilities are owned by the subsidiaries, including Cambrex Charles City, Inc, Cambrex Karlskoga AB and Cambrex Profarmaco Milano S.r.l.
Get a free copy of the Zacks research report on Cambrex (CBM)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Cambrex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cambrex and related companies with MarketBeat.com's FREE daily email newsletter.